產(chǎn)品名稱 | DC101 |
---|---|
商品貨號 | B164339 |
Organism | Rattus norvegicus (B cell); Mus musculus (myeloma), rat (B cell); mouse (myeloma) |
Tissue | Spleen |
Cell Type | hybridoma |
Product Format | frozen |
Morphology | lymphoblast |
Culture Properties | suspension |
Biosafety Level | 1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
Strain | Lewis (B cell); BALB/c (myeloma) |
Applications | DC101 was found to be specific for the murine tyrosine kinase receptor FLK-1. ELISA data showed that the antibody bound to purified FLK-1:SEAP but not alkaline phosphatase or other receptor tyrosine kinases such as FLK-2. Treatment with DC101 antibody completely inhibits the growth of established epidermoid, glioblastoma, pancreatic, and renal human tumor xenografts by suppression of tumor-induced neovascularization |
Storage Conditions | liquid nitrogen vapor phase |
Disclosure | This material is cited in a US or other Patent and may not be used to infringe the claims. Depending on the wishes of the Depositor, ATCC may be required to inform the Patent Depositor of the party to which the material was furnished. This material may not have been produced or characterized by ATCC. |
Derivation | Animals were hyperimmunized with an immune complex consisting of the mouse FLK-1:SEAPs soluble receptor, a rabbit anti-alkaline phosphatase polyclonal antibody and Protein-G sepharose beads. Spleen cells were fused with NS-1 mouse myeloma cells. |
Genes Expressed | immunoglobulin; monoclonal antibody; against murine vascular endothelial growth factor (VEGF) receptor-2 (Flk-1/KDR) |
Cellular Products | immunoglobulin; monoclonal antibody; against murine vascular endothelial growth factor (VEGF) receptor-2 (Flk-1/KDR) |
Comments | DC101 was found to be specific for the murine tyrosine kinase receptor FLK-1. ELISA data showed that the antibody bound to purified FLK-1:SEAP but not alkaline phosphatase or other receptor tyrosine kinases such as FLK-2. DC101 does not cross-react with the human VEGFR2/KDR. Treatment with DC101 antibody completely inhibits the growth of established epidermoid, glioblastoma, pancreatic, and renal human tumor xenografts by suppression of tumor-induced neovascularization |
Complete Growth Medium | The base medium for this cell line is ATCC-formulated Dulbecco's Modified Eagle's Medium, Catalog No. 30-2002. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
|
Subculturing | Protocol: Cultures can be maintained by the addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 2 X 10 exp5 viable cells/ml. Maintain cell density between 1 X 10 exp5 and 1 X 10 exp6 viable cells/ml. Medium Renewal: Every 2 to 3 days |
Cryopreservation | Freeze medium: Complete growth medium 92.5%; DMSO, 7.5% Storage temperature: liquid nitrogen vapor phase |
Culture Conditions | Temperature: 37.0°C |
Isotype | IgG1; kappa light chain |
Name of Depositor | ImClone Systems Inc. |
Deposited As | rat (B cell); mouse (myeloma) |
U.S. Patent Number | |
References | Rockwell P, Goldstein NI. Monoclonal antibodies specific to VEGF receptors and uses thereof. US Patent 5,955,311 dated Sep 21 1999 Witte L, et al. Monoclonal antibodies targeting the VEGF receptor-2 (Flk1/KDR) as an anti-angiogenic therapeutic strategy. Cancer Metastasis Rev. 17: 155-161, 1998. PubMed: 9770111 Prewett M, et al. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. Cancer Res. 59: 5209-5218, 1999. PubMed: 10537299 Shaheen RM, et al. Effects of an antibody to vascular endothelial growth factor receptor-2 on survival, tumor vascularity, and apoptosis in a murine model of colon carcinomatosis. Int. J. Oncol. 18: 221-226, 2001. PubMed: 11172585 Kadambi A, et al. Vascular endothelial growth factor (VEGF)-C differentially affects tumor vascular function and leukocyte recruitment: role of VEGF-receptor 2 and host VEGF-A. Cancer Res. 61: 2404-2408, 2001. PubMed: 11289105 Kozin SV, et al. Vascular endothelial growth factor receptor-2-blocking antibody potentiates radiation-induced long-term control of human tumor xenografts. Cancer Res. 61: 39-44, 2001. PubMed: 11196192 Zimmermann RC, et al. Preovulatory treatment of mice with anti-VEGF receptor 2 antibody inhibits angiogenesis in corpora lutea. Microvasc. Res. 62: 15-25, 2001. PubMed: 11421657 Klement G, et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J. Clin. Invest. 105: R15-R24, 2000. PubMed: 10772661 Stoelcker B, et al. VEGF/Flk-1 interaction, a requirement for malignant ascites recurrence. J. Inferon Cytokine Res. 20: 511-517, 2000. PubMed: 10841080 |
梅經(jīng)理 | 17280875617 | 1438578920 |
胡經(jīng)理 | 13345964880 | 2438244627 |
周經(jīng)理 | 17757487661 | 1296385441 |
于經(jīng)理 | 18067160830 | 2088210172 |
沈經(jīng)理 | 19548299266 | 2662369050 |
李經(jīng)理 | 13626845108 | 972239479 |